Farmas USA

DVAX
Que opinais del brutal porcentaje de cortos 10618 acciones short respecto a un total de 38432 acciones. La tengo en el punto de mira, pero cuándo he visto esto...ufff

MACK

Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients

http://investors.merrimackpharma.com/releasedetail.cfm?ReleaseID=1005127

20% abajo en PM, igual la zona de 3,9x-4 puede dar para rebote

INO

Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study

http://finance.yahoo.com/news/inovio-zika-vaccine-generates-robust-130000813.html

El día que pasen de sus fases 1 (14 ni más ni menos) a fases 2 será la rehostia...

LXRX

http://seekingalpha.com/news/3231901-lexicon-pharmas-sotagliflozin-successful-second-late-stage-study-type-1-diabetics-shares-13?uprof=45#email_link

TIG

Takeda makes €10 million equity investment in TiGenix - 11m share at €0.858 or ~23% above market close

"These additional funds will further strengthen our financial position allowing us to remain fully focused on progressing with the marketing authorization application of Cx601 in Europe, the launch of our Phase III trial to register Cx601 in the United States and advancing with the other clinical assets in our pipeline," concluded Eduardo Bravo.

In connection with the issuance of the New Shares and the resulting capital increase, the board of directors has cancelled the preferential subscription rights of existing shareholders for the benefit of Takeda Pharmaceuticals International AG.

http://finance.yahoo.com/news/takeda-makes-10-million-equity-210502767.html

Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and p

Read more at:
http://thefly.com/landingPageNews.php?id=2480209

que los cortos te hagan estar mas atento pero no inmovilizado.

vendi HZNP, no estoy comodo con ese gap pendiente de cerrar.

mantengo orden de compra en 15,26

y el stop loss en 3,80 para la mierda de PACB